FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304091733> ?p ?o ?g. }

• W4304091733 endingPage "e0275794" @default.
• W4304091733 startingPage "e0275794" @default.
• W4304091733 abstract "Multipurpose prevention technologies (MPTs), which prevent sexually transmitted infection(s) and unintended pregnancy, are highly desirable to women. In this randomized, placebo-controlled, phase I study, women used a placebo or tenofovir (TFV) and levonorgestrel (LNG) intravaginal ring (IVR), either continuously or cyclically (three, 28-day cycles with a 3 day interruption in between each cycle), for 90 days. Sixty-eight women were screened; 47 were randomized to 4 arms: TFV/LNG or placebo IVRs used continuously or cyclically (4:4:1:1). Safety was assessed by adverse events and changes from baseline in mucosal histology and immune mediators. TFV concentrations were evaluated in multiple compartments. LNG concentration was determined in serum. Modeled TFV pharmacodynamic antiviral activity was evaluated in vaginal and rectal fluids and cervicovaginal tissue ex vivo . LNG pharmacodynamics was assessed with cervical mucus quality and anovulation. All IVRs were safe with no serious adverse events nor significant changes in genital tract histology, immune cell density or secreted soluble proteins from baseline. Median vaginal fluid TFV concentrations were >500 ng/mg throughout 90d. TFV-diphosphate tissue concentrations exceeded 1,000 fmol/mg within 72hrs of IVR insertion. Mean serum LNG concentrations exceeded 200 pg/mL within 2h of TFV/LNG use, decreasing quickly after IVR removal. Vaginal fluid of women using TFV-containing IVRs had significantly greater inhibitory activity (87–98% versus 10% at baseline; p<0.01) against HIV replication in vitro . There was a >10-fold reduction in HIV p24 antigen production from ectocervical tissues after TFV/LNG exposure. TFV/LNG IVR users had significantly higher rates of anovulation, lower Insler scores and poorer/abnormal cervical mucus sperm penetration. Most TFV/LNG IVR users reported no change in menstrual cycles or fewer days of and/or lighter bleeding. All IVRs were safe. Active rings delivered high TFV concentrations locally. LNG caused changes in cervical mucus, sperm penetration, and ovulation compatible with contraceptive efficacy. Trial registration: ClinicalTrials.gov #NCT03279120 ." @default.
• W4304091733 created "2022-10-10" @default.
• W4304091733 creator A5024613253 @default.
• W4304091733 creator A5025731778 @default.
• W4304091733 creator A5030525692 @default.
• W4304091733 creator A5031286794 @default.
• W4304091733 creator A5032897934 @default.
• W4304091733 creator A5035617477 @default.
• W4304091733 creator A5037385700 @default.
• W4304091733 creator A5043044043 @default.
• W4304091733 creator A5048400225 @default.
• W4304091733 creator A5049231965 @default.
• W4304091733 creator A5051095413 @default.
• W4304091733 creator A5054975290 @default.
• W4304091733 creator A5058050986 @default.
• W4304091733 creator A5061594892 @default.
• W4304091733 creator A5068614516 @default.
• W4304091733 creator A5076589614 @default.
• W4304091733 creator A5082007029 @default.
• W4304091733 creator A5087235619 @default.
• W4304091733 creator A5089446248 @default.
• W4304091733 date "2022-10-10" @default.
• W4304091733 modified "2023-09-30" @default.
• W4304091733 title "Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study" @default.
• W4304091733 cites W1272557987 @default.
• W4304091733 cites W1627535092 @default.
• W4304091733 cites W182689329 @default.
• W4304091733 cites W1877697862 @default.
• W4304091733 cites W188541297 @default.
• W4304091733 cites W1895220657 @default.
• W4304091733 cites W1910585352 @default.
• W4304091733 cites W1941748532 @default.
• W4304091733 cites W1963960283 @default.
• W4304091733 cites W1964884058 @default.
• W4304091733 cites W1965398194 @default.
• W4304091733 cites W1967059888 @default.
• W4304091733 cites W1970786548 @default.
• W4304091733 cites W1978934985 @default.
• W4304091733 cites W1988491543 @default.
• W4304091733 cites W1993023130 @default.
• W4304091733 cites W2005311204 @default.
• W4304091733 cites W2015636840 @default.
• W4304091733 cites W2015768353 @default.
• W4304091733 cites W2027655222 @default.
• W4304091733 cites W2035012695 @default.
• W4304091733 cites W2043161810 @default.
• W4304091733 cites W2049528804 @default.
• W4304091733 cites W2069582117 @default.
• W4304091733 cites W2074308401 @default.
• W4304091733 cites W2077097712 @default.
• W4304091733 cites W2080732718 @default.
• W4304091733 cites W2082801131 @default.
• W4304091733 cites W2083131792 @default.
• W4304091733 cites W2083308537 @default.
• W4304091733 cites W2089000881 @default.
• W4304091733 cites W2090325912 @default.
• W4304091733 cites W2095157572 @default.
• W4304091733 cites W2095844669 @default.
• W4304091733 cites W2119838983 @default.
• W4304091733 cites W2121288293 @default.
• W4304091733 cites W2131549796 @default.
• W4304091733 cites W2142727155 @default.
• W4304091733 cites W2146478787 @default.
• W4304091733 cites W2146634980 @default.
• W4304091733 cites W2149522605 @default.
• W4304091733 cites W2161496228 @default.
• W4304091733 cites W2230897456 @default.
• W4304091733 cites W2275067150 @default.
• W4304091733 cites W2290010664 @default.
• W4304091733 cites W2295442039 @default.
• W4304091733 cites W2297998233 @default.
• W4304091733 cites W2395897911 @default.
• W4304091733 cites W2406896521 @default.
• W4304091733 cites W2410289324 @default.
• W4304091733 cites W2415160747 @default.
• W4304091733 cites W2502502188 @default.
• W4304091733 cites W2558446330 @default.
• W4304091733 cites W2565524772 @default.
• W4304091733 cites W2569075054 @default.
• W4304091733 cites W2605353187 @default.
• W4304091733 cites W2792298605 @default.
• W4304091733 cites W2810390464 @default.
• W4304091733 cites W2811198017 @default.
• W4304091733 cites W2899740934 @default.
• W4304091733 cites W2946395116 @default.
• W4304091733 cites W2960534569 @default.
• W4304091733 cites W3188571791 @default.
• W4304091733 cites W4220938896 @default.
• W4304091733 cites W4247837837 @default.
• W4304091733 cites W4302509461 @default.
• W4304091733 doi "https://doi.org/10.1371/journal.pone.0275794" @default.
• W4304091733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36215267" @default.
• W4304091733 hasPublicationYear "2022" @default.
• W4304091733 type Work @default.
• W4304091733 citedByCount "5" @default.
• W4304091733 countsByYear W43040917332023 @default.
• W4304091733 crossrefType "journal-article" @default.
• W4304091733 hasAuthorship W4304091733A5024613253 @default.

• next